الصفحة الرئيسية>>AGN 193109 (sodium salt)

AGN 193109 (sodium salt) (Synonyms: CD3106)

رقم الكتالوجGC42748

AGN 193109 is a potent antagonist of retinoic acid receptors (RARs; Kd = 2, 2, and 3 nM for RARα, β, and γ, respectively).

Products are for research use only. Not for human use. We do not sell to patients.

AGN 193109 (sodium salt) التركيب الكيميائي

الحجم السعر المخزون الكميّة
500μg
170٫00
متوفر
1mg
321٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

AGN 193109 is a potent antagonist of retinoic acid receptors (RARs; Kd = 2, 2, and 3 nM for RARα, β, and γ, respectively). It is selective for RARs over retinoid X receptors (RXRs; Kd = >10,000 nM for human RXRα, β, and γ receptors). AGN 193109 reverses changes in cell morphology induced by the RAR agonist TTNPB in ECE16-1 human endometrial ectocervical epithelial cells. It also reverses the growth suppressive effects of all-trans-RA, 13-cis-RA, and 9-cis-RA when used at a 10-fold molar excess. AGN 193109 decreases expression of cytokeratin K5-8, 13, 14, 16, 17, and 19 genes, markers of retinoid action in ECE16-1 cells, when co-administered with TTNPB but not when used alone. In vivo, AGN 193109 induces cleft palate or frontonasal dysplasia and eye malformations in fetuses of pregnant mice following a single oral dose of 1 mg/kg.

مراجعات

Review for AGN 193109 (sodium salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AGN 193109 (sodium salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.